drugset
drugset / Trial / NCT07800520

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

NCT07800520 ↗

Phase 1 Recruiting 110 enrolled Yale University National Institute on Drug Abuse (NIDA) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls.

Timeline

Start
2026-10-01
Primary completion
2030-08
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Background [11C]OMAR Diagnostic / imaging agent 740 mbq —

Indications

substance-related disorder